NASDAQ:IMRN Immuron (IMRN) Stock Price, News & Analysis $0.98 -0.05 (-4.65%) Closing price 04:00 PM EasternExtended Trading$0.90 -0.08 (-7.85%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC Filings About Immuron Stock (NASDAQ:IMRN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Immuron alerts:Sign Up Key Stats Today's Range$0.95▼$1.0450-Day Range$0.98▼$1.8452-Week Range$0.68▼$2.35Volume21,374 shsAverage Volume74,466 shsMarket Capitalization$7.93 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Immuron Limited (NASDAQ:IMRN) is an Australian biopharmaceutical company focused on developing and commercializing orally delivered immunotherapies. Its products are based primarily on antibodies derived from hyperimmune bovine colostrum and are designed to act locally in the gastrointestinal tract rather than enter the bloodstream. The company’s leading product is Travelan, an oral treatment intended to help prevent travelers’ diarrhea caused by enterotoxigenic Escherichia coli (ETEC). Travelan has been marketed in several countries, including the United States, Canada, and Australia, subject to the regulatory status and labeling requirements in each jurisdiction. Immuron also conducts research on additional oral antibody-based therapies for gastrointestinal and infectious diseases. Its development programs have included candidates such as IMM-124E and IMM-529, which have been investigated for potential applications involving gastrointestinal disorders and infections. The company is headquartered in Melbourne, Australia, and serves international markets through regulatory, commercial, and distribution activities.AI Generated. May Contain Errors. Read More Immuron Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks12th Percentile Overall ScoreIMRN MarketRank™: 0.58838844051 of 5 starsImmuron scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingImmuron has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageImmuron has only been the subject of 1 research reports in the past 90 days.Read more about Immuron's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioImmuron has a P/B Ratio of 1.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.82% of the float of Immuron has been sold short.Short Interest Ratio / Days to CoverImmuron has a short interest ratio ("days to cover") of 0.56, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Immuron has recently decreased by 46.62%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmuron does not currently pay a dividend.Dividend GrowthImmuron does not have a long track record of dividend growth. News and Social Media2.3 / 5News Sentiment0.66 News SentimentImmuron has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Immuron this week, compared to 1 article on an average week. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Immuron insiders have not sold or bought any company stock.Percentage Held by Insiders7.01% of the stock of Immuron is held by insiders.Percentage Held by Institutions0.12% of the stock of Immuron is held by institutions.Read more about Immuron's insider trading history. Receive IMRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immuron and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMRN Stock News HeadlinesImmuron Calls November AGM to Decide Board Seats, Incentive Plan and Capital-Raising CapacityOctober 16 at 8:32 AM | tipranks.comImmuron Reports Phase 2 Travelan Results Published In Scientific Reports; Stock DownOctober 13 at 9:01 AM | rttnews.comI'm giving you a space stock today. Free.On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any regular brokerage account gives investors exposure to SpaceX and 66 of its neighbors, without an IPO allocation. He is also naming two space stocks he would consider dumping before December, plus a $14 stock that Elon has personally put his name on.October 16 at 1:00 AM | Behind the Markets (Ad)Immuron Limited Reports Nature Scientific Reports Publication of Phase 2 Travelan Study Showing Reduced ETEC-Related Adverse EventsOctober 13 at 6:31 AM | quiverquant.comQTravelan® Phase 2 Study Results PublishedOctober 13 at 6:00 AM | globenewswire.comImmuron advances Travelan after Phase 2 data published in Nature journalOctober 12, 2026 | tipranks.comImmuron Ltd ADR (IMRN)September 26, 2026 | investing.comImmuron Releases Comprehensive 2026 Annual ReportSeptember 24, 2026 | tipranks.comSee More Headlines IMRN Stock Analysis - Frequently Asked Questions How have IMRN shares performed this year? Immuron's stock was trading at $0.7680 on January 1st, 2026. Since then, IMRN shares have increased by 27.9% and is now trading at $0.9821. How were Immuron's earnings last quarter? Immuron (NASDAQ:IMRN) posted its quarterly earnings results on Friday, August, 14th. The company reported ($0.08) earnings per share (EPS) for the quarter. The business had revenue of $1.27 million for the quarter. When did Immuron IPO? Immuron (IMRN) raised $6 million in an initial public offering (IPO) on Friday, June 9th 2017. The company issued 600,000 shares at $9.99 per share. Joseph Gunnar and Rodman & Renshaw (a unit of H.C. Wainwright & Co.) served as the underwriters for the IPO and WallachBeth Capital was co-manager. How do I buy shares of Immuron? Shares of IMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Immuron own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immuron investors own include Inovio Pharmaceuticals (INO), Alibaba Group (BABA), GE Aerospace (GE), Sorrento Therapeutics (SRNE), Canopy Growth (CGC), Gilead Sciences (GILD) and CrowdStrike (CRWD). Company Calendar Last Earnings8/14/2026Today10/16/2026Fiscal Year End6/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 2 weeks, IMRN's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IMRN CIK1660046 Webwww.immuron.com.au Phone(138) 892-4854Fax6103 98227735Employees7Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio7.26 Quick Ratio5.98 Sales & Book Value Annual Sales$5.47 million Price / Sales1.45 Cash FlowN/A Price / Cash FlowN/A Book Value$0.94 per share Price / Book1.04Miscellaneous Outstanding Shares8,070,000Free Float7,505,000Market Cap$7.93 million OptionableNot Optionable Beta1.09 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:IMRN) was last updated on 10/16/2026 by MarketBeat.com Staff. From Our PartnersElon Musk’s 4th Wealth Window Set to Open by October 30Jeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...Brownstone Research | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredSpaceX minted 4400 millionaires in a single daySpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into milliona...Behind the Markets | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredUndiscovered Sub-$1 Gold-Silver Royalty Stock Takes FlightA small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...Digest Publishing | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredThis high yielding “gold annuity” is starting to move…Garrett Goggin, a 20+ year gold analyst, has called major moves before: Montage Gold up 2,567%, G2 Goldfields ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immuron Please log in to your account or sign up in order to add this asset to your watchlist. Share Immuron With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
